SCHEMBL30206122

SCHEMBL30206122

CNc1nc(Nc2ccc(N3CCOCC3)cc2C)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 3/20 0.42
▸ TTK P33981 5/20 0.40
▸ ALK Q9UM73 3/20 0.40
▸ INSR P06213 2/20 0.40
▸ PTK2 Q05397 5/20 0.39
▸ MAPK8 P45983 2/20 0.39
▸ MAPK9 P45984 2/20 0.39
▸ MAPK10 P53779 2/20 0.39
▸ CDC7 O00311 1/20 0.39
▸ PLK4 O00444 1/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ DCLK1 O15075 1/20 0.39
▸ PDPK1 O15530 1/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ DYRK3 O43781 1/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ PRKD3 O94806 1/20 0.39
▸ PAK4 O96013 1/20 0.39
▸ CHEK2 O96017 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173575 1.00 LRRK2 (0.42) LRRK2TTKALKINSRPTK2
SCHEMBL29173409 0.93 LRRK2 (0.51) LRRK2TTKALKINSRPTK2
SCHEMBL30206251 0.93 LRRK2 (0.51) LRRK2TTKALKINSRPTK2
SCHEMBL29173445 0.92 ZAP70 (0.43) LRRK2ALKINSRPTK2MAPK8
SCHEMBL29173600 0.92 LRRK2 (0.47) LRRK2TTKALKINSRPTK2
SCHEMBL30206325 0.92 LRRK2 (0.47) LRRK2TTKALKINSRPTK2
SCHEMBL24944156 0.92 MAPK9 (0.40) LRRK2TTKALKINSRPTK2
SCHEMBL29173512 0.90 PKMYT1 (0.40) LRRK2ALKINSRAURKAJAK2
SCHEMBL30206202 0.90 PKMYT1 (0.40) LRRK2ALKINSRAURKAJAK2
SCHEMBL29173608 0.87 PKMYT1 (0.38) LRRK2ALKINSRAURKAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 LRRK2 3283/4885TTK 183/4885ALK 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback